DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., … Kantarjian, H. M. (2018). Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study. In Clinical Lymphoma Myeloma and Leukemia (Vol. 18, pp. S204–S205). Elsevier BV. https://doi.org/10.1016/j.clml.2018.07.057

DiNardo, Courtney D., Eytan M. Stein, Stéphane de Botton, Gail J. Roboz, Jessica K. Altman, Alice S. Mims, Ronan Swords, et al. “Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.” In Clinical Lymphoma Myeloma and Leukemia, 18:S204–5. Elsevier BV, 2018. https://doi.org/10.1016/j.clml.2018.07.057.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2018. p. S204–5.

DiNardo, Courtney D., et al. “Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.” Clinical Lymphoma Myeloma and Leukemia, vol. 18, Elsevier BV, 2018, pp. S204–05. Crossref, doi:10.1016/j.clml.2018.07.057.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2018. p. S204–S205.